Stockscreener 앱 받기
3.99
2.31%
0.09
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus
Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com
OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
OnKure Therapeutics has cash runway into 2029 - BizWest
JonesTrading Maintains OnKure Therapeutics(OKUR.US) With Hold Rating - Moomoo
OnKure Therapeutics reports Q2 2026 net loss $15.3M; $176.4M cash runway into 2029 - TradingView
OKUR: IND-enabling PI3Ka programs advance toward 2027 filings, backed by $176M cash runway into 2029 - TradingView
OnKure Therapeutics, Inc. Q2 2026: Net loss $(30.5M) for 6M, EPS $(0.31) — 10-Q Summary - TradingView
OnKure Therapeutics (Nasdaq: OKUR) raises $150M to fund PI3Kα drugs - Stock Titan
OKUR: Q2 2026 net loss was $15.3M; cash reserves strengthened by $150M private placement - TradingView
OnKure Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Yahoo Finance
OnKure Therapeutics Rings the Closing Bell - Nasdaq
OnKure Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - TradingView
Vivo Capital LLC Invests $7.98 Million in OnKure Therapeutics, Inc. $OKUR - marketbeat.com
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Balance Sheet - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR|Onkure Therapeutics Inc|Price:4.050|Chg%:-0.070 - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OnKure Therapeutics (OKUR) Slips 1.7% as Shares Test Key Support ZoneNAAIM Leverage - dars.gov.et
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Cash Flow - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Onkure Therapeutics Inc (OKUR) Income Statement - TradingKey
OKUR Options Volatility — NASDAQ:OKUR - TradingView
OKUR Options Chain — NASDAQ:OKUR - TradingView
Price to earnings forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
Price to sales forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes - Investing.com
OKUR Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
OnKure Therapeutics Price Target Cut to $21.00/Share From $27.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Miss Streak - dars.gov.et
OnKure Therapeutics (OKUR) Declines 2.7% as Shares Test Key Support ZoneRip Sell Trade - dars.gov.et
Enterprise value to revenue forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near - Yahoo Finance
We're Not Very Worried About OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - Sahm
Price to book forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks - TradingView
Enterprise value to EBITDA forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 - The Manila Times
OnKure lines up July 15 virtual event on cancer-drug design - Stock Titan
OnKure Therapeutics to host virtual event on Ju... - Pluang
OnKure Therapeutics (OKUR) Slips 2% as Stock Tests Support Near $4.24Factor ETF Flow - dars.gov.et
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 2000 Index - marketscreener.com
OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Completeness Index - marketscreener.com
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 3000 Index - marketscreener.com
OnKure Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:OKUR) - TradingView
OnKure Therapeutics (OKUR) Gains 2.13% as Stock Holds Above Key SupportInstitutional Volume - dars.gov.et
OKUR Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC) - The Globe and Mail
OnKure Therapeutics president and CEO sells $378 in stock By Investing.com - Investing.com Nigeria
OnKure Therapeutics president and CEO sells $378 in stock - Investing.com
OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock - Investing.com
Form 4 Onkure Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock By Investing.com - Investing.com Nigeria
[Form 4] OnKure Therapeutics, Inc. Insider Trading Activity - Stock Titan
0.52%
0.07%
자본화:
|
볼륨(24시간):